Cod Liver Oil and Glucosamine for Arthritis UK

Written by Chris Jones, Social Media Manager at Nutrivity with 7+ years in the supplement industry.

Cod Liver Oil and Glucosamine for Arthritis UK — What the Evidence Shows

Arthritis is the most common cause of disability in the UK. The Arthritis Research UK foundation estimates that over 10 million people in the UK are affected by some form of arthritis, with osteoarthritis accounting for the majority of cases. The condition significantly impacts quality of life — limiting mobility, disrupting sleep, affecting mental health, and in severe cases preventing people from working or living independently.

Conventional arthritis management in the UK focuses on pain relief through paracetamol and NSAIDs, physiotherapy, weight management, and — for severe joint degeneration — joint replacement surgery. This pharmaceutical approach is effective for symptom control, but long-term NSAID use carries significant risks: gastrointestinal irritation and bleeding, elevated cardiovascular risk, and renal effects are all well-documented consequences of sustained NSAID use in older adults, who represent the majority of OA patients.

Cod liver oil and glucosamine together represent one of the most well-evidenced natural approaches to daily arthritis management — each addressing a distinct aspect of joint pathology through mechanisms that complement rather than duplicate each other. This guide covers what the evidence shows for each ingredient in the context of arthritis and how the combination works. For a full overview of how both ingredients work together, see our guide to what is cod liver oil and glucosamine. For joint health evidence specifically, see our guide to cod liver oil for joint health UK. For full product information, visit our Cod Liver Oil and Glucosamine product page.

Understanding the Two Pathological Processes in Osteoarthritis

Osteoarthritis is not simply “wear and tear” — the traditional description understates the biological complexity of the condition. OA involves two distinct and interacting pathological processes that both require management for effective treatment.

The first is the structural component: progressive degradation of articular cartilage. In OA, the balance between cartilage matrix synthesis by chondrocytes and cartilage matrix degradation by metalloproteinase enzymes (MMPs) and aggrecanases shifts toward net degradation. Over years and decades, this produces progressive thinning of the cartilage layer, eventually exposing subchondral bone and producing the bone-on-bone friction associated with severe OA. This structural degeneration is what shows on X-ray as joint space narrowing.

The second is the inflammatory component: synovial inflammation. The synovial membrane lining the joint becomes chronically inflamed in OA — a state called synovitis — driven by the same pro-inflammatory mediators (prostaglandins, cytokines including TNF-α and IL-1β, and leukotrienes) that characterise inflammatory arthritis. Synovial inflammation is responsible for the warmth, swelling, and much of the pain associated with OA flares, and it directly contributes to the upregulation of cartilage-degrading enzymes — creating a cycle where inflammation accelerates structural degeneration.

Effective arthritis management addresses both processes. Cod liver oil’s omega-3 fatty acids address the inflammatory process. Glucosamine sulphate addresses the structural process. This dual-mechanism coverage is why the combination is more comprehensively evidence-supported for arthritis management than either ingredient alone.

The Clinical Evidence for Cod Liver Oil in Arthritis

The most direct evidence for cod liver oil in osteoarthritis comes from the Cardiff University OA trial, published in the peer-reviewed journal Rheumatology. This double-blind, placebo-controlled trial examined patients with knee OA who were scheduled for joint replacement surgery — representing patients with established, clinically significant disease. After 12 weeks of cod liver oil supplementation, 86% of patients in the cod liver oil group showed significant reductions in enzymes directly responsible for cartilage degradation — specifically aggrecanase-1, aggrecanase-2, and collagenase-1. These enzymes are the primary mediators of cartilage matrix breakdown in OA. Their reduction in the cod liver oil group compared to placebo suggests that cod liver oil’s omega-3 fatty acids do not merely reduce pain but may actually slow the enzymatic cartilage destruction process.

Pain scores were also significantly reduced in the cod liver oil group, and a higher proportion of the cod liver oil group showed histological improvement in cartilage quality at the time of surgery compared to the placebo group. This is unusually direct evidence — examining actual cartilage tissue from patients who had their joint replaced, comparing those who took cod liver oil versus those who did not.

For rheumatoid arthritis — the autoimmune inflammatory form — the omega-3 evidence base is particularly well-developed. Multiple systematic reviews and meta-analyses of omega-3 supplementation in RA have found consistent reductions in morning stiffness duration, tender joint count, swollen joint count, and NSAID requirements in patients taking fish oil or cod liver oil versus placebo. A 2012 meta-analysis published in Annals of the Rheumatic Diseases, pooling data from multiple RCTs, found significant improvements across all key RA outcome measures. The NSAID-sparing effect is clinically significant — allowing patients to reduce NSAID doses and thereby reduce NSAID-associated gastrointestinal and cardiovascular risk.

The Clinical Evidence for Glucosamine in Arthritis

The glucosamine sulphate evidence for osteoarthritis is led by the landmark Reginster trial published in The Lancet. Over three years, 1500mg glucosamine sulphate daily produced zero significant joint space narrowing versus progressive narrowing in the placebo group — structural disease modification that no NSAID or analgesic has demonstrated in clinical trials. This is the most clinically meaningful finding in the supplement literature for osteoarthritis: that a nutritional supplement can slow the structural progression of cartilage loss.

The GUIDE trial showed glucosamine sulphate producing superior functional improvements to both paracetamol and placebo over six months in knee OA patients. The WOMAC functional index improvements reflect real-world meaningful changes in ability to perform daily activities — climbing stairs, walking, bending — that define quality of life for people with OA. The European EULAR guidelines endorse glucosamine sulphate as first-line pharmacological management for knee OA with the highest evidence level.

For a full breakdown of the glucosamine evidence and timeline, see our guide to how long does glucosamine take to work.

Arthritis Types — Where the Evidence Applies

It is important to be precise about which arthritis types the evidence applies to. Both cod liver oil and glucosamine sulphate have the strongest evidence for osteoarthritis — the degenerative, non-autoimmune form affecting the knees, hips, hands, and spine. Knee OA is the most studied joint for both ingredients.

For rheumatoid arthritis, the omega-3 evidence from cod liver oil is well-supported as a complementary approach alongside prescribed DMARD therapy. Glucosamine’s evidence is primarily for OA rather than RA, though it may provide structural support for joints affected by RA alongside disease-modifying treatment. RA requires medical management with DMARDs and often biologics — cod liver oil and glucosamine are complementary to, not substitutes for, this treatment.

For psoriatic arthritis, ankylosing spondylitis, and other inflammatory arthropathies, the omega-3 anti-inflammatory mechanism of cod liver oil may provide some benefit, but these conditions have disease-specific management requirements that should be led by a rheumatologist.

Practical Guidance for Arthritis Management

Cod liver oil and glucosamine are not substitutes for prescribed arthritis treatment, medical supervision, or physiotherapy. They are most appropriately used as evidence-based daily nutritional supplements alongside conventional management — potentially reducing analgesic requirements over time, supporting the structural integrity of joints, and addressing the nutritional deficiencies (particularly vitamin D) that are common in people with arthritis and that may worsen joint symptoms.

The timeline for benefit differs between the two. Cod liver oil’s anti-inflammatory effect begins to develop within 4–8 weeks of consistent daily supplementation. Glucosamine’s structural effect takes considerably longer — meaningful symptomatic improvement at 8–12 weeks, with structural preservation demonstrable only over months to years. Starting both together provides early benefit from the omega-3 component while glucosamine’s structural support builds.

Osteoarthritis vs Rheumatoid Arthritis — Different Conditions, Different Priorities

It is worth being explicit about the distinction between osteoarthritis and rheumatoid arthritis because their management priorities differ and the evidence for cod liver oil and glucosamine applies differently to each.

Osteoarthritis is a degenerative condition driven by mechanical wear, age-related chondrocyte decline, and the slow loss of cartilage matrix integrity. Both cod liver oil (anti-inflammatory omega-3) and glucosamine sulphate (structural substrate) have direct mechanistic relevance and clinical trial evidence for OA. The combination addresses OA’s two core pathological processes comprehensively.

Rheumatoid arthritis is an autoimmune condition where the immune system attacks the synovial membrane, causing severe inflammatory joint destruction. RA requires disease-modifying antirheumatic drugs (DMARDs) — methotrexate, hydroxychloroquine, leflunomide, and for more severe cases, biological DMARDs targeting TNF-α or IL-6. These treatments are non-negotiable for preventing the progressive joint destruction that characterises uncontrolled RA. Cod liver oil has meaningful evidence as a complementary anti-inflammatory supplement in RA — reducing morning stiffness and NSAID requirements alongside DMARDs — but is not a substitute for DMARD therapy. Glucosamine’s structural evidence is primarily for OA rather than RA.

If you have been diagnosed with rheumatoid arthritis rather than osteoarthritis, discuss any supplements with your rheumatologist to ensure they complement rather than complicate your prescribed treatment plan.

Summary — Cod Liver Oil and Glucosamine for Arthritis

Cod liver oil and glucosamine sulphate address the two distinct pathological processes of osteoarthritis — synovial inflammation and cartilage structural degradation — through complementary mechanisms. The Cardiff University trial provides direct evidence that cod liver oil reduces cartilage-degrading enzyme activity in OA patients. The Reginster Lancet trial provides direct evidence that glucosamine sulphate preserves structural joint space over three years. Together they represent one of the most evidence-supported natural approaches to arthritis management available in the UK — used consistently daily as part of a comprehensive management strategy that includes appropriate medical supervision, physiotherapy, and lifestyle measures.

For full product information and to purchase, visit Nutrivity’s Cod Liver Oil and Glucosamine product page.

Frequently Asked Questions